Tag: Novo Nordisk A/S

Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Here’s an update on our 4th Industrial Revolution stocks and the rest of the portfolio

Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Russia’s war on Ukraine puts women off having children — and that could spell economic disaster

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial

Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China

Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs